Takeda presents positive results from trial of chronic kidney disease treatment
June 10, 2025Research and Development European Renal Association, Immunology, Nephrology, Takeda, autoimmune disease, immunoglobulin A nephropathy (IgAN), kidney disease
Takeda Pharmaceuticals has announced positive results from a proof-of-concept study of mezagitamab (TAK-079) to treat patients with primary immunoglobulin A …
ANGLE’s Parsortix system used in new cancer biology research
June 10, 2025Medical Communications, Research and Development Angle, Oncology, Parsortix system, R&D, biotech, oncology, scientific journals
ANGLE has announced three new peer-reviewed publications demonstrating the use of its Parsortix circulating tumour cell (CTC) harvesting system in …
Hansa Biopharma to host investor event on Guillain-Barré Syndrome to accelerate research
June 10, 2025Conferencing, Events & Incentives, Interactive Conferences, Medical Communications, Research and Development, Sales and Marketing Guillain-Barré syndrome, Hansa Biopharma, Immunology, Neurology, investor event
Hansa Biopharma (Hansa) will host a virtual investor event on Guillain-Barré syndrome (GBS) on 16 June 2025. The webcast aims …
Vertex presents promising new data from cystic fibrosis trials
June 9, 2025Medical Communications, Research and Development European Cystic Fibrosis Conference, Rare Diseases, Vertex, clinical trial, cystic fibrosis
Vertex Pharmaceuticals has presented new data showing the clinical and quality-of-life benefits of its cystic fibrosis (CF) therapies, particularly Alyftrek …
Corcept reports survival benefit in ALS trial of dazucorilant despite missing primary endpoint
June 9, 2025Research and Development Corcept Therapeutics, European Network to Cure ALS (ENCALS), Neurology, amyotrophic lateral sclerosis, clinical trial
Corcept Therapeutics has announced results from its phase 2 DAZALS study investigating dazucorilant in patients with amyotrophic lateral sclerosis (ALS), …
Study into treatment for rare condition in premature infants launches globally
June 9, 2025Research and Development Chiesi Farmaceutici, Elgan Pharma, Gastrointestinal tract, Paediatrics, clinical trial, intestinal malabsorption, premature infant health
Elgan Pharma, specialising in neonatology, and Italy-based biopharma, Chiesi Farmaceutici, have announced the dosing of the first participating infants in …
The unbearable lightness of creativity
June 9, 2025Medical Communications, Sales and Marketing 21GRAMS, Atomic Matter, Corporate, HAVAS LYNX, London UK, PM Society Awards, Pharmacy, pharma healthcare communications, pharma marketing
21GRAMS and Havas Lynx lead the charge at the PM Society Awards for pharma marketing and healthcare communications Commenting on …
Trial into rare genetic disease Werner syndrome reports promising results
June 6, 2025Research and Development Chiba University, Niagen Bioscience, Rare Diseases, Werner Syndrome, clinical trial, rare genetic disease
Researchers at Chiba University, Japan, alongside Niagen Bioscience, have reported successful results from the world’s first trial of nicotinamide riboside …
Osivax reaches key milestone in phase 2a trial for broad-spectrum flu vaccine
June 6, 2025Research and Development Ghent University Hospital, Osivax, Vaccine, Virology, clinical trial, influenza a
Osivax has announced the completion of patient visits in its phase 2a trial evaluating a booster dose of OVX836, a …
BioNTech and Bristol Myers Squibb collaborate on bispecific antibody for solid tumours
June 6, 2025Research and Development BioNTech, Oncology, bispecific antibody treatment, bristol myers squibb, oncology, partnership
BioNTech and Bristol Myers Squibb (BMS) have entered a partnership to collaboratively develop and commercialise BNT327, BioNTech’s bispecific antibody, to …
Roche’s Evrysdi tablet approved in EU for spinal muscular atrophy
June 5, 2025Research and Development European Commission, Evrysdi, Neurology, Roche, european union, neuromuscular condition, spinal muscular atrophy (SMA)
Roche has received approval from the European Commission for a new tablet formulation of Evrysdi (risdiplam), marking the first and …
Study links COVID-19 and some vaccines to increased risk of rare neurological condition
June 5, 2025Medical Communications, Medical Education, Medical/ Scientific Writing, Research and Development COVID-19, COVID-19 vaccine, Guillain-Barré Syndrome (GBS), Neurology, Virology, adenoviral vector vaccines, mRNA-based vaccines, medical study, neurological condition
An international study has found an increased risk of Guillain-Barré syndrome (GBS) following SARS-CoV-2 infection and after vaccination with adenoviral …
Brenntag acquires mcePharma to expand GMP capabilities in biopharma services
June 5, 2025Manufacturing and Production, Mergers and Acquisitions Brenntag Specialities, Corporate, acquisition, continuous monitoring platform (CMP), mcePharma
Brenntag Specialties has acquired Czech-based mcePharma, strengthening its position in the pharma and biopharma industries through expanded continuous monitoring platform …
EU regulatory momentum could catalyse clinical trial innovation
June 5, 2025Regulatory Affairs, Research and Development AI, Corporate, EU regulation, Hospital Management, Pharmacy, Veeva Systems
Dr Werner Engelbrecht at Veeva Systems discusses how compliance can be turned into a competitive advantage with connected platforms and …
NIPRO introduces LiniXia water treatment system for dialysis clinics
June 4, 2025Research and Development European Renal Association (ERA) Congress, LiniXia, LiniXia PRO, NIPRO, Nephrology, dialysis clinics, water treatment
Japan-based biopharma, NIPRO, has launched LiniXia, a new reverse osmosis (RO) water treatment system for haemodialysis. It was unveiled at …
Astellas selects Veeva Vault CRM as global commercial platform
June 4, 2025Business Services, Technical Consultancy Astrellas, Corporate, Customer Relationship Management (CRM), Pharmacy, Vault CRM, Veeva Vault CRM, business services, cloud software
Astellas has selected Veeva Vault CRM as its global customer relationship management (CRM) platform, with Veeva China CRM deployed specifically …
Evosep launches high-throughput proteomics platform Evosep Eno
June 4, 2025Business Services, Mergers and Acquisitions, Research and Development, Translation Services Evosep, Pharmacy, biotech platform
Evosep has launched Evosep Eno, a new high-throughput separation platform designed to support next-generation workflows in liquid chromatography-mass spectrometry (LC-MS)-based …
LEO Pharma initiates phase 2a trial of delgocitinib cream for rare skin condition
June 3, 2025Research and Development Dermatology, LEO Pharma, Skin, clinical trial, delgocitinib cream, rare skin condition
LEO Pharma has initiated a phase 2a trial investigating delgocitinib cream in adults with mild-to-severe palmoplantar pustulosis (PPP). The DELTA …
Sanofi to acquire Blueprint, advancing therapy for rare immunological diseases
June 3, 2025Mergers and Acquisitions, Research and Development Blueprint Medicines, Immunology, Rare Diseases, Sanofi, advanced systemic mastocytosis (ASM), indolent systemic mastocytosis (ISM), rare immunological diseases
Sanofi and Blueprint Medicines Corporation, a US biopharma, have entered into an agreement under which Sanofi will acquire Blueprint. This …
New CAR T Vision Coalition and roadmap report to launch at ASCO aims to double patients treated with CAR T-cell therapy by 2030
June 3, 2025Research and Development American Society of Clinical Oncology, CAR T Vision, CAR T-cell therapy, International Myeloma Foundation, Kite, Leukemia & Lymphoma Society, Oncology, blood cancer
For people living with aggressive blood cancers, CAR T-cell therapy offers hope for a longer, healthier life, and for some, …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
